Compugen Second Quarter 2012 Conference Call Scheduled for Tuesday, August 7, 2012 at 10:00 AM EDT
July 30 2012 - 8:38AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
will host a conference call at 10:00 AM EDT on Tuesday, August 7,
2012 to review second quarter 2012 results. The quarterly results
will be released on the Company’s website (www.cgen.com), prior to
the conference call.
To access the conference call, please dial 1-888-668-9141 from
the US, or + 972-3-9180609 internationally. The call will also be
available via live webcast through Compugen’s website, located at
the following link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-326-9310 from the US or
+972-3-925-904 internationally. The replay will be available
through August 10, 2012.
About CompugenCompugen is a leading therapeutic product
discovery company focused on therapeutic proteins and monoclonal
antibodies to address important unmet needs in the fields of
immunology and oncology. Unlike traditional high throughput trial
and error experimental based drug candidate discovery, Compugen
utilizes a broad and continuously growing infrastructure of
proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer) prediction and
selection of product candidates. Selected product candidates are
then advanced in its Pipeline Program to the pre-IND stage. The
Company's business model primarily involves collaborations covering
the further development and commercialization of product candidates
from its Pipeline Program and various forms of research and
discovery agreements, in both cases providing Compugen with
potential milestone payments and royalties on product sales or
other forms of revenue sharing. In 2012, Compugen established
operations in California for the development of oncology and
immunology monoclonal antibody therapeutic candidates against
Compugen-discovered drug targets. In 2002, Compugen established an
affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN.TA), to
utilize certain of the Company's in silico predictive discovery
capabilities in agricultural biotechnology. For additional
information, please visit Compugen's corporate website at
www.cgen.com.
This press release may contain “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include words such as “may”, “expects”,
“anticipates”, “believes”, and “intends”, and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
discussed in the "Risk Factors" section Compugen’s Annual Report on
Form 20-F for the year ended December 31, 2011 as filed with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Oct 2023 to Oct 2024